Auris Medical (EARS) Stock Price, Quote, News and Overview
NASDAQ:EARS - Nasdaq -
EARS Quote, Performance and Key Statistics
3.045
-0.06 (-1.77%)
The current stock price of EARS is 3.045 null. In the past month the price decreased by -13.49%. In the past year, price increased by 204.56%.
EARS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About EARS
Company Profile
Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 9 full-time employees. The company went IPO on 2014-08-06.
Company Info
Auris Medical
Bahnhofstrasse 21
Zug ZUG HM 11 CH
CEO: Thomas Meyer
Employees: 9
Company Website: https://aurismedical.com/
Phone: 410612011350.0
Auris Medical / EARS FAQ
What is the stock price of Auris Medical today?
The current stock price of EARS is 3.045 null. The price decreased by -1.77% in the last trading session.
What is the ticker symbol for Auris Medical stock?
The exchange symbol of Auris Medical is EARS and it is listed on the Nasdaq exchange.
On which exchange is EARS stock listed?
EARS stock is listed on the Nasdaq exchange.
What is Auris Medical worth?
Auris Medical (EARS) has a market capitalization of 34.76M null. This makes EARS a Nano Cap stock.
How many employees does Auris Medical have?
Auris Medical (EARS) currently has 9 employees.
What are the support and resistance levels for Auris Medical (EARS) stock?
Auris Medical (EARS) has a support level at 2.96 and a resistance level at 3.27. Check the full technical report for a detailed analysis of EARS support and resistance levels.
Should I buy Auris Medical (EARS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EARS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EARS, evaluating the profitability, health, valuation and growth aspects
- Auris Medical (EARS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Auris Medical (EARS) Sales and EPS estimates to see what analysts future expectations are.
- Auris Medical (EARS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Auris Medical (EARS) Insider and Institutional Ownership to learn about the owners and their transactions.
- Auris Medical (EARS) Stock Chart to make your own analysis
- Auris Medical (EARS) Latest news and press-releases to stay up to date.
Does Auris Medical (EARS) stock pay dividends?
EARS does not pay a dividend.
What is the Price/Earnings (PE) ratio of Auris Medical (EARS)?
Auris Medical (EARS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.45).
EARS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to EARS. When comparing the yearly performance of all stocks, EARS is one of the better performing stocks in the market, outperforming 94.61% of all stocks.
EARS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to EARS. Both the profitability and financial health of EARS have multiple concerns.
EARS Financial Highlights
Over the last trailing twelve months EARS reported a non-GAAP Earnings per Share(EPS) of -1.45. The EPS increased by 36.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -105.84% | ||
| ROE | N/A | ||
| Debt/Equity | 0.01 |